APOM and COVID-19: We tested this hypothesis in mice using an LPS model, as well as in leveraged patient samples from the Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a) trial to test whether SGLT2i randomization was associated with preserved ApoM vs standard of care (SOC).